LAMIVUDINE AND ZIDOVUDINE

Post-LOE

Cipla

ANDAORALTABLET

Approved

Sep 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LAMIVUDINE AND ZIDOVUDINE by Cipla is [see microbiology ( )]. Approved for combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (hiv-1) infection, combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2018.

Drug data last refreshed 19h ago

Mechanism of Action

[see Microbiology ( )].

Indications (2)

combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV-1) infection combination with other antiretroviral agents for the treatment of HIV-1 infection

Worked on LAMIVUDINE AND ZIDOVUDINE at Cipla? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.